224 related articles for article (PubMed ID: 27036030)
1. MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
Lassalle S; Zangari J; Popa A; Ilie M; Hofman V; Long E; Patey M; Tissier F; Belléannée G; Trouette H; Catargi B; Peyrottes I; Sadoul JL; Bordone O; Bonnetaud C; Butori C; Bozec A; Guevara N; Santini J; Hénaoui IS; Lemaire G; Blanck O; Vielh P; Barbry P; Mari B; Brest P; Hofman P
Oncotarget; 2016 May; 7(21):30461-78. PubMed ID: 27036030
[TBL] [Abstract][Full Text] [Related]
2. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
Romeo P; Colombo C; Granata R; Calareso G; Gualeni AV; Dugo M; De Cecco L; Rizzetti MG; Zanframundo A; Aiello A; Carcangiu ML; Gloghini A; Ferrero S; Licitra L; Greco A; Fugazzola L; Locati LD; Borrello MG
Endocr Relat Cancer; 2018 Mar; 25(3):217-231. PubMed ID: 29298817
[TBL] [Abstract][Full Text] [Related]
3. Two GEO MicroRNA Expression Profile Based High-Throughput Screen to Identify MicroRNA-31-3p Regulating Growth of Medullary Thyroid Carcinoma Cell by Targeting RASA2.
Jiang M; Shi X; Zhu H; Wei W; Li J
Med Sci Monit; 2019 Jul; 25():5170-5180. PubMed ID: 31298226
[TBL] [Abstract][Full Text] [Related]
4. YAP confers resistance to vandetanib in medullary thyroid cancer.
Wang H; Tang J; Su Z
Biochem Cell Biol; 2020 Jun; 98(3):443-448. PubMed ID: 32449862
[TBL] [Abstract][Full Text] [Related]
5. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC.
Shabani N; Razaviyan J; Paryan M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
Hum Pathol; 2018 Sep; 79():212-221. PubMed ID: 29885402
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
Starenki D; Hong SK; Wu PK; Park JI
Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408
[TBL] [Abstract][Full Text] [Related]
8. A miRNA signature associated with human metastatic medullary thyroid carcinoma.
Santarpia L; Calin GA; Adam L; Ye L; Fusco A; Giunti S; Thaller C; Paladini L; Zhang X; Jimenez C; Trimarchi F; El-Naggar AK; Gagel RF
Endocr Relat Cancer; 2013 Dec; 20(6):809-23. PubMed ID: 24127332
[TBL] [Abstract][Full Text] [Related]
9. Upregulated miR-9-3p Promotes Cell Growth and Inhibits Apoptosis in Medullary Thyroid Carcinoma by Targeting BLCAP.
Chen Y; Zhang S; Zhao R; Zhao Q; Zhang T
Oncol Res; 2017 Sep; 25(8):1215-1222. PubMed ID: 27938505
[TBL] [Abstract][Full Text] [Related]
10. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
Chu YH; Hardin H; Schneider DF; Chen H; Lloyd RV
Exp Mol Pathol; 2017 Oct; 103(2):229-236. PubMed ID: 29107050
[TBL] [Abstract][Full Text] [Related]
12. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma.
Szczyrba J; Nolte E; Wach S; Kremmer E; Stöhr R; Hartmann A; Wieland W; Wullich B; Grässer FA
Mol Cancer Res; 2011 Jun; 9(6):791-800. PubMed ID: 21593139
[TBL] [Abstract][Full Text] [Related]
14. Validation of miRNAs as diagnostic and prognostic biomarkers, and possible therapeutic targets in medullary thyroid cancers.
Mondin A; Bertazza L; Barollo S; Pedron MC; Manso J; Piva I; Basso D; Merante Boschin I; Iacobone M; Pezzani R; Mian C; Censi S
Front Endocrinol (Lausanne); 2023; 14():1151583. PubMed ID: 37361540
[TBL] [Abstract][Full Text] [Related]
15. Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in
Mancikova V; Montero-Conde C; Perales-Paton J; Fernandez A; Santacana M; Jodkowska K; Inglada-Pérez L; Castelblanco E; Borrego S; Encinas M; Matias-Guiu X; Fraga M; Robledo M
Clin Cancer Res; 2017 Mar; 23(5):1334-1345. PubMed ID: 27620278
[No Abstract] [Full Text] [Related]
16. MicroRNA-21 promotes proliferation, migration, and invasion of colorectal cancer, and tumor growth associated with down-regulation of sec23a expression.
Li C; Zhao L; Chen Y; He T; Chen X; Mao J; Li C; Lyu J; Meng QH
BMC Cancer; 2016 Aug; 16():605. PubMed ID: 27495250
[TBL] [Abstract][Full Text] [Related]
17. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
18. circPVT1 regulates medullary thyroid cancer growth and metastasis by targeting miR-455-5p to activate CXCL12/CXCR4 signaling.
Zheng X; Rui S; Wang XF; Zou XH; Gong YP; Li ZH
J Exp Clin Cancer Res; 2021 May; 40(1):157. PubMed ID: 33962657
[TBL] [Abstract][Full Text] [Related]
19. Assessment of
Pishkari S; Hadavi R; Koochaki A; Razaviyan J; Paryan M; Hashemi M; Mohammadi-Yeganeh S
Horm Mol Biol Clin Investig; 2021 Mar; 42(3):265-271. PubMed ID: 33769725
[TBL] [Abstract][Full Text] [Related]
20. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
[Next] [New Search]
